NCT06400290

Brief Summary

ORBITA-MOON is a double-blinded, placebo-controlled experimental study that aims to understand how the different coronary artery stenoses contribute to overall clinical angina in patients with multi-vessel coronary artery disease. This study will investigate the symptoms conferred by each stenosis, induced by experimental ischaemia, for 60 patients with multi-vessel coronary artery disease.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
11mo left

Started Jun 2024

Typical duration for not_applicable

Geographic Reach
1 country

9 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress68%
Jun 2024Apr 2027

First Submitted

Initial submission to the registry

April 24, 2024

Completed
12 days until next milestone

First Posted

Study publicly available on registry

May 6, 2024

Completed
1 month until next milestone

Study Start

First participant enrolled

June 13, 2024

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2027

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2027

Last Updated

June 6, 2025

Status Verified

June 1, 2025

Enrollment Period

2.6 years

First QC Date

April 24, 2024

Last Update Submit

June 5, 2025

Conditions

Keywords

AnginaMulti-vessel coronary artery diseaseSymptomsPlacebo-controlled symptom assessment

Outcome Measures

Primary Outcomes (1)

  • Placebo-controlled similarity score during induced ischaemia at the coronary stenosis

    The patient scores the similarity of the angina experienced during the experimental balloon inflation procedure against the angina experienced before the procedure between 0-10 (Higher Score = Most similar)

    Intra-procedural

Secondary Outcomes (16)

  • Placebo-controlled intensity score during induced ischaemia at the coronary stenosis

    Intra-procedural

  • Angina symptom type during induced ischaemia at the coronary stenosis

    Intra-procedural

  • Change in angina symptom score

    57 days

  • Angina severity as assessed by Canadian Cardiovascular Society Class

    57 days

  • Angina severity as assessed by MRC dyspnoea scale

    57 days

  • +11 more secondary outcomes

Study Arms (1)

Patients with stable angina

EXPERIMENTAL

Patients who: 1. Are symptomatic with angina 2. Have anatomically severe multi-vessel coronary artery disease 3. Have physiological evidence of myocardial ischaemia

Procedure: Percutaneous coronary intervention (PCI)Diagnostic Test: Symptom assessment during experimentally induced ischaemia

Interventions

Coronary artery stenting for stable angina

Patients with stable angina

Transient experimental balloon occlusion across coronary stenosis to determine the symptoms conferred by ischaemia at this stenosis.

Patients with stable angina

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Eligibility for PCI due to angina
  • Anatomical evidence of significant multi-vessel coronary stenosis defined by either:
  • ≥70% stenosis in two or more coronary arteries of ≥2.5mm visual diameter stenosis, on invasive coronary angiography (ICA)
  • Severe stenosis in ≥2 coronary arteries of ≥ 2.5mm visual diameter stenosis, on CTCA
  • Physiological evidence of ischaemia with a positive test corresponding to the coronary arteries to be stented, on at least one of the following:
  • dobutamine stress echocardiogram
  • cardiac MRI
  • myocardial perfusion study
  • invasive metrics of coronary physiology

You may not qualify if:

  • Recent acute coronary syndrome
  • Previous coronary artery by-pass graft surgery (CABG)
  • Significant left main stem disease
  • Chronic total occlusion in the target artery(s)
  • Moderate to severe valvular disease
  • Moderate to severe left ventricular impairment
  • Contraindication to PCI or a drug-eluting stents
  • Contraindication to antiplatelet therapy
  • Contraindication to adenosine
  • Pregnant
  • Inability to consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Essex Cardiothoracic Centre

Basildon, United Kingdom

RECRUITING

Royal Bournemouth Hospital

Bournemouth, United Kingdom

RECRUITING

Royal Sussex County Hospital

Brighton, BN2 5BE, United Kingdom

RECRUITING

Imperial College NHS Trust

London, United Kingdom

RECRUITING

Royal Free London NHS Foundation Trust

London, United Kingdom

RECRUITING

St Georges University Hospital

London, United Kingdom

RECRUITING

Nottingham City Hospital

Nottingham, NG5 1PB, United Kingdom

RECRUITING

Portsmouth Hospitals University NHS Trust

Portsmouth, United Kingdom

NOT YET RECRUITING

University Hospital Southampton

Southampton, SO16 6YD, United Kingdom

RECRUITING

MeSH Terms

Conditions

Angina, StableAngina Pectoris

Interventions

Percutaneous Coronary Intervention

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesChest PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Endovascular ProceduresVascular Surgical ProceduresCardiovascular Surgical ProceduresSurgical Procedures, OperativeMinimally Invasive Surgical Procedures

Study Officials

  • Rasha Al-Lamee, PhD MRCP

    Imperial College London

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Shayna Chotai, MBBS MRCP

CONTACT

Rasha Al-Lamee, PhD MRCP

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
Participants and outcomes assessors will be briefly blinded during the experimental research procedure, during the placebo-controlled balloon inflations when they are asked to report their symptoms. Once the inflations have been completed, all patients will go on to have stents and the blinded part of the protocol will be over.
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Model Details: All participants will partake in the same research protocol.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 24, 2024

First Posted

May 6, 2024

Study Start

June 13, 2024

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

April 1, 2027

Last Updated

June 6, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations